4568 JP

DAIICHI SANKYO CO LTD

Healthcare


Presented:03/14/2024
Price:¥4,701.00
Cap:$75.30B
Current Price:¥4,966.00
Cap:$79.20B

Presented

Date03/14/2024
Price¥4,701.00
Market Cap$75.30B
Ent Value$57.35B
P/E Ratio48.45x
Book Value¥827.32
Div Yield0.74%
Shares O/S1,917.45M
Ave Daily Vol4,423,528
Short IntN/A

Current

Price¥4,966.00
Market Cap$79.20B
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Publicly traded companies mentioned herein: AbbVie Inc (ABBV), AstraZeneca PLC (AZN), Daiichi Sankyo Co Ltd (4568 JP), Merck & Co Inc (MRK)

Highlights

The presenter is long shares of Daiichi Sankyo Co Ltd (4568 JP), a premier antibody drug conjugate (ADC) developer that is aiming to replace non-targeted chemotherapy treatments with targeted chemotherapy. Beyond the company’s base business, there is a path to realize significant upside from several recent and pipeline assets. These include its 50% ownership of a $25B asset (Enhertu), 50% of a $17.5B asset (Dato-DXd), and the $22B deal with Merck for its next three pipeline assets. As such, he sees upside from the current ¥4,700 share price to ¥11,000, with various catalysts throughout the year driving the stock. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.